Toronto, Ontario – The Newswire – January 2, 2023 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Corporation"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce the appointment of Dr. Alvira Macanovic as President and CEO of the Corporation effective January 1, 2023.  Dr. George Adams will continue as Executive-Chairman of the Corporation with responsibilities for new applications, investor relations and strategic partnerships.

“In 2022 Ventripoint has transitioned from a development company to a fully operating and commercialization company with a worldwide customer base and it is now time for an operational CEO to drive the Corporation forward,” stated Dr. George Adams, Executive-Chairman. “I will be focusing on strategic issues and governance for the Corporation.”

"It has been my great pleasure to work with the Ventripoint team, stated Dr. Alvira Macanovic, President and CEO.  “I look forward to leading the company through this next phase and continuing our mission to improve the lives of heart patients worldwide." 

Dr. Macanovic has had increasing responsibilities within the Corporation since her appointment as Manager of Regulatory Affairs & Quality Assurance in 2017. She has been instrumental in building the current cohesive teams for manufacturing, sales and marketing, development, quality assurance, and regulatory affairs as the Vice-President of Operations, as well as effectively engaging the cardiology community and driving strategic partnerships.  

She has over 15 years of experience in pharmaceutical and medical device related industries where she has worked with researchers, start-ups, SMEs, and multi-national companies to commercialize medical products. Previously, Dr. Macanovic worked for an organization supported through the Centers of Excellence for Commercialization and Research in various leadership roles, including business development, sales, and commercialization strategy the commercialization of medical imaging technologies. She obtained a Bachelor of Science in Biochemistry from McGill University and a PhD in Chemistry from Concordia University.  

The Board of Directors has granted Dr. Macanovic 250,000 options at an exercise price of $.30 with a lifespan of 10 years and vesting equally over three years.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Dr. George Adams

gadams@ventripoint.com

519-803-6937

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.